Inavolisib
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 74 publications
Expert consensus on detection and clinical application of alterations in PIK3CA/AKT1/PTEN genes (2026 edition)
Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]
Published: October 25, 2026
In Silico Discovery of a Potential PI3Kα Inhibitor Incorporating an Imidazole Moiety for Breast Cancer Treatment.
Journal: Current issues in molecular biology
Published: August 21, 2026
Targeting PI3Kα with Small Molecules: Progress and Challenges in Tumor Treatment.
Journal: Current issues in molecular biology
Published: August 20, 2026
Inavolisib: a second-generation PI3Kα inhibitor in HR+/HER2-negative breast cancer.
Journal: Expert opinion on drug metabolism & toxicology
Published: July 24, 2026
Evolving First-Line Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: CDK4/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms.
Journal: Current oncology (Toronto, Ont.)
Published: May 19, 2026
The Phosphatidylinositol 3-Kinase (PI3K) Inhibitor Inavolisib Has Breast-cancer Synergy Combined With Recombinant Methioninase But Not on Normal Cells.
Journal: In vivo (Athens, Greece)
Published: May 06, 2026
Inavolisib for PIK3CA-mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: April 27, 2026
Economic Evaluation of Inavolisib Combined With Palbociclib-Fulvestrant for PIK3CA-Mutated, HR+/HER2- Advanced Breast Cancer in USA.
Journal: Technology in cancer research & treatment
Published: April 16, 2026
Inavolisib and lenvatinib for PIK3CA-mutated refractory splenic angiosarcoma: a case report.
Journal: Anti-cancer drugs
Published: April 15, 2026
PIK3CA mutant cervical cancer is selectively suppressed by PI3Kα inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy.
Journal: Neoplasia (New York, N.Y.)
Published: April 01, 2026
Class-level DILI saturation and hERG-driven risk stratification among 2024-2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis.
Journal: Investigational new drugs
Published: March 16, 2026
Last Updated: 11/08/2026